Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,369.44
    +201.37 (+0.50%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,478.27
    +183.33 (+0.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,541.29
    +10.69 (+0.70%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

India's Gennova developing Omicron-specific COVID-19 vaccine

FILE PHOTO: 3D-printed small toy figurines, a syringe and vial labelled "coronavirus disease (COVID-19) vaccine" are seen in front of India flag in this illustration

By Krishna N. Das

NEW DELHI (Reuters) - India's Gennova Biopharmaceuticals is working on an Omicron-specific mRNA COVID-19 vaccine candidate, it told Reuters on Monday, after a person with direct knowledge of the matter said the product could be ready in a month or two.

"The Omicron-specific variant of the vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals," a company spokesperson said in a text message. "We will keep you posted."

The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out.

ADVERTISEMENT

Pfizer Inc said last week a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant could be ready to launch by March.

Gennova said that on Friday it submitted to India's drug regulator phase 2 trial data for its original mRNA vaccine candidate. The government said last year that product was found to be "safe, tolerable, and immunogenic" in the participants of an initial study.

If given emergency-use approval, this would be the country's first mRNA COVID-19 vaccine like the ones developed by Pfizer and Moderna.

(Reporting by Krishna N. Das; Editing by Kenneth Maxwell, Kirsten Donovan)